Streetbeat News

DNA

Ginkgo Bioworks Holdings, Inc.

https://www.ginkgobioworks.com

Industry

Biotechnology

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Open

8.30

Mkt cap

472M

Volume

498K

High

8.56

P/E Ratio

-0.47

52-wk high

75.20

Low

8.13

Div yield

N/A

52-wk low

5.26

U.S. stocks were mixed on Monday, with the Dow Jones index gaining around 300 points. However, several notable stocks, including ResMed, Coinbase Global, and Nvidia, experienced significant declines. ResMed shares fell sharply by 10.4% following a downgrade from Citigroup and sleep apnea data from Lilly. Other stocks such as Molecular Partners, Cryoport, BridgeBio Pharma, BitFuFu, Inspire Medical Systems, Ginkgo Bioworks, MicroStrategy, Paymentus Holdings, Super Micro Computer, and Sirius XM Holdings also saw notable declines.

Portfolio Pulse from Avi Kapoor

June 24, 2024 | 5:18 pm

Ginkgo Bioworks Holdings' shares are trading lower following a report issued by a popular newsletter.

Portfolio Pulse from Benzinga Newsdesk

May 31, 2024 | 2:04 pm

Cathie Wood's ARK Innovation ETF (ARKK) has seen a sharp decline, with a 72% drop since its peak in February 2021. Among its top holdings, only Tesla has shown a positive return. The ten largest losers within ARKK include Ginkgo Bioworks, Teladoc Health, Pacific Biosciences, 10x Genomics, Unity Technologies, Verve Therapeutics, Zoom Video, Roku, UiPath, and Intellia Therapeutics.

Portfolio Pulse from Kaustubh Bagalkote

May 28, 2024 | 11:29 am

Ginkgo Bioworks Holdings (NYSE:DNA) has seen a 7.94% increase in its short percent of float, now at 23.51%. This indicates a bearish sentiment among investors, as it would take traders 5.39 days to cover their short positions. The company's short interest is significantly higher than its peers, whose average is 3.34%.

Portfolio Pulse from Benzinga Insights

May 23, 2024 | 3:00 pm

Ark Investment Management, led by Cathie Wood, is facing significant underperformance in 2024, with its flagship ETF ARKK trading over 70% below its all-time high. Investment advisor Ram Ahluwalia criticizes Ark's strategy, highlighting missed bets and an over-reliance on 'vision' over fundamentals. Key ETFs like ARKG and ARKQ are also underperforming compared to the broader market.

Portfolio Pulse from Shanthi Rexaline

May 20, 2024 | 10:51 am

BTIG analyst Mark Massaro has downgraded Ginkgo Bioworks Holdings (NYSE:DNA) from Neutral to Sell.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 5:02 pm

Morgan Stanley analyst Tejas Savant maintains an Equal-Weight rating on Ginkgo Bioworks Holdings (NYSE:DNA) but lowers the price target from $2 to $1.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 2:25 pm

Ginkgo Bioworks Holdings' shares surged following a continued listing standard notice from the NYSE and potential influence from 'Roaring Kitty's' return to social media, which may have boosted high-short interest stocks.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 2:44 pm

TeraWulf Inc. reported disappointing Q1 results, leading to a 9.3% drop in pre-market trading. Other companies like StoneCo, TMC the metals company, MMTec, Kingsoft Cloud, Cognyte Software, Ginkgo Bioworks, Maplebear, and Burford Capital also saw pre-market declines after various announcements.

Portfolio Pulse from Avi Kapoor

May 14, 2024 | 9:24 am

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) received a notice from the NYSE on May 7, 2024, for not complying with the minimum average closing price requirement of $1 per share over a consecutive 30 trading-day period. Despite this, Ginkgo's Class A common stock continues to trade on the NYSE.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 8:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.